Merrimack Pharmaceuticals Inc (NASDAQ:MACK)
| 5.89 Data as of Jul 22 |  -0.01 / -0.17%Today’s Change | 2.05 Today|||52-Week Range 8.25 | +10.49% Year-to-Date |
Latest MACK News | Press Releases
No recent news for Merrimack Pharmaceuticals Inc.
Today’s Trading
| Previous close | 5.90 |
| Today’s open | 5.97 |
| Day’s range | 5.86 - 6.10 |
| Volume | 779,120 |
| Average volume (3 months) | 2,351,108 |
| Market cap | $610.1M |
| Dividend yield | -- |
Data as of 3:59pm ET, 07/22/2014
Growth & Valuation
| Earnings growth (last year) | -5.32% |
| Earnings growth (this year) | +12.25% |
| Earnings growth (next 5 years) | +5.61% |
| Revenue growth (last year) | -2.32% |
| P/E ratio | NM |
| Price/Sales | 11.04 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| VTLVital Therapies Inc | -0.56 | -2.05% |
| OREXOrexigen Therapeutic... | -0.10 | -1.86% |
| NLNKNewLink Genetics Cor... | +0.33 | +1.58% |
| OMEDOncoMed Pharmaceutic... | +0.43 | +2.00% |
Data as of 4:00pm ET, 07/22/2014
Financials
| Next reporting date | August 8, 2014 |
| EPS forecast (this quarter) | -$0.30 |
| Annual revenue (last year) | $47.8M |
| Annual profit (last year) | -$130.9M |
| Net profit margin | -273.98% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Robert J. Mulroy |
Senior Vice President- Operations William M. McClements |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
